News Opinion Editor's Corner ACC 2025 What’s Going to Be Hot at ACC 2025? Michael O'Riordan March 26, 2025
News Conference News ACC 2024 IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM Caitlin E. Cox April 15, 2024
News Conference News ACC 2024 Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI Shelley Wood April 06, 2024
News Conference News ACC 2023 Wearable Device Helps HF Patients Avoid Coming Back to the Hospital: BMAD Caitlin E. Cox March 06, 2023
News Conference News ACC 2022 Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term Shelley Wood April 03, 2022
News Conference News ACC 2022 Seasonal, but No Year-round Help for HF With Flu Shots: IVVE Yael L. Maxwell April 03, 2022
News Conference News ACC 2022 SODIUM-HF: No Impact of Tighter Dietary Salt Restriction on Death or Hospitalization L.A. McKeown April 02, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Conference News ACC 2022 What’s Going to Be Hot at ACC 2022, In Person or Virtual Shelley Wood March 28, 2022
News Conference News ACC 2021 Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients Shelley Wood May 16, 2021
News Conference News ACC 2021 PARADISE-MI: ARNI Doesn’t Surpass ACE Inhibitor After Acute MI L.A. McKeown May 15, 2021
News Conference News ACC 2020 A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA Michael O'Riordan March 28, 2020
News Conference News ACC 2016 Vagus Nerve Stimulation Fails to Improve Clinical Outcomes in Chronic Heart Failure Todd Neale April 05, 2016